UnknownPhase 1NCT05829057
The IIT Study of Evaluation of P-IL-2 Single Agent and With Anti-PD-1
Studying Carcinoma of esophagus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Zhejiang University
- Principal Investigator
- weijia weijiastem cell and somatic cell clinical study committee
- Intervention
- Intravenous injection of P-IL-2(biological)
- Enrollment
- 10 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2023 – 2025
Study locations (1)
- First affiliated hospital, Zhejiang University, Hangzhou, Zhejiang, China
Collaborators
Zcapsule Pharmaceuticals (Shaoxing) Co., Ltd
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05829057 on ClinicalTrials.govOther trials for Carcinoma of esophagus
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNANCT06990178Adaptive Neoadjuvant Therapy for Esophageal CancerCancer Hospital Chinese Academy of Medical Science, Shenzhen Center
- RECRUITINGNCT07464470Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal CancersBlokhin's Russian Cancer Research Center
- RECRUITINGNANCT07307560High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea PatientsZhejiang University
- ENROLLING BY INVITATIONEARLY PHASE1NCT07371247Based on ctDNA-MRD Guided Adjuvant Treatment Escalation After Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Study on Safety and EfficacyThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE3NCT07217704Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.SOFIE
- ACTIVE NOT RECRUITINGPHASE2NCT07339488Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell CarcinomaChuangzhen Chen
- RECRUITINGPHASE2NCT07205731Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell CarcinomaUniversity Hospital, Clermont-Ferrand
- RECRUITINGPHASE2NCT07071103Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid TumorsChuangzhen Chen